#vaccine research

The PreHevbrio vaccine produces higher antibody levels and offers faster protection.

The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.

An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.

The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.

The protein vaccine was 96% effective against the original SARS-CoV-2 coronavirus, but less so against new variants.

Messenger RNA vaccines—also called mRNA vaccines—are some of the first COVID-19 vaccines authorized for use in the United States.

Social media posts that make misleading comparisons undermine the science behind the COVID-19 vaccine.

In the United States, an FDA expert advisory panel voted on December 10 to recommend emergency use authorization.

The vaccine from the University of Oxford and AstraZeneca uses a chimpanzee adenovirus vector.

With the first vaccines expected within weeks, a CDC advisory panel votes on how to prioritize access.

Moderna has requested emergency use authorization for its mRNA vaccine candidate.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

Vaccine development is proceeding at an unprecedented pace, but could still hit snags on the way to approval.

Upcoming hearing on the Pfizer/BioNTech vaccine will be livestreamed on YouTube, Facebook and Twitter.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

FDA weighs whether to resume coronavirus vaccine trial halted due to an adverse event.